Business
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
Combination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium Inc. (Nasdaq: EQ), a clinical-stage
About this update from Equillium, Inc.
[{"type":"text","content":"\nCombination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference will take place at the George R. Brown Convention Center in Houston, Texas from November 6 to 10, 2024.\n\nTitle: Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses\nPresenting Author: Phoi Tiet, Senior Research Associate, Equillium, Inc.\nAbstract Number: 908\nLocation: Exhibit Halls A & B\nDate: Saturday, November 9, 2024\n\nThe abstract highlights that cytokines are a focus of anti-cancer therapeutic development due to their central role in regulating anti-tumoral immune responses, and that data demonstrates that IL-15 and IL-21 synergistically augment NK and CD8 T cells activities, which further enhanced their proliferation and cytolytic function. With the ability to rescue T cell dysfunction, this cytokine combination could be a promising treatment approach to stimulating anti-tumor immune responses.\n\nAbout Multi-Cytokine Platform and Multi-Cytokine Inhibitors EQ101 & EQ302\n\nOur proprietary multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. This approach is expected to avoid the broad immuno-suppression and off-target safety liabilities that may be associated with other therapeutic classes, such as Janus kinase inhibitors. Many immune-mediated diseases are driven by the same combination of dysregulated cytokines, and we believe identifying the key cytokines for these diseases will allow us to target and develop customized treatment strategies for multiple autoimmune and inflammatory diseases.\n\nCurrent platform assets include EQ101, a clinical stage, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9, and IL-15 for intravenous and subcutaneous delivery and EQ302, a preclinical stage, first-in-class, selective, bi-specific ...